Biologic treatments in Takayasu's Arteritis: A comparative study of tumor necrosis factor inhibitors and tocilizumab

Basit Öğe Kaydı
dc.authoridKanıtez, Nilüfer Alpay/0000-0003-1185-5816
dc.authoridInce, Burak/0000-0001-9813-2228
dc.authoridAksu, Kenan/0000-0001-8889-2688
dc.authoridYazıcı, Ayten/0000-0003-2167-4509
dc.authorwosidOnen, Fatos/AAA-8970-2021
dc.authorwosidKanıtez, Nilüfer Alpay/W-7332-2019
dc.authorwosidKaymaz Tahra, Sema/GPP-1272-2022
dc.authorwosidCefle, Ayse/AAT-3653-2020
dc.authorwosidInce, Burak/AAT-7850-2020
dc.authorwosidAksu, Kenan/HLH-8218-2023
dc.authorwosidYazıcı, Ayten/AAT-3636-2020
dc.contributor.authorAlibaz-Oner, Fatma
dc.contributor.authorKaymaz-Tahra, Sema
dc.contributor.authorBayindir, Ozun
dc.contributor.authorYazici, Ayten
dc.contributor.authorInce, Burak
dc.contributor.authorKalkan, Kubra
dc.contributor.authorKanitez, Nilufer Alpay
dc.date.accessioned2024-06-12T11:15:58Z
dc.date.available2024-06-12T11:15:58Z
dc.date.issued2021
dc.departmentTrakya Üniversitesien_US
dc.description.abstractObjective: To compare the treatment outcomes of TNF inhibitors and tocilizumab (TCZ) in patients with Takayasu arteritis. Methods: Takayasu arteritis patients who were refractory to conventional immunosuppressive (IS) drugs and received biologic treatment were included in this multicenter retrospective cohort study. Clinical, laboratory and imaging data during follow-up were recorded. Remission, glucocorticoid (GC) sparing effect, drug survival was compared between TNF inhibitor and TCZ treatments. Also, a subgroup matched comparison was performed between groups. Results: One hundred and eleven (F/M: 98/13) patients were enrolled. A total of 173 biologic treatment courses (77 infliximab, 49 TCZ, 33 adalimumab, 9 certolizumab, 3 rituximab, 1 ustekinumab and 1 anakinra) were given. Tocilizumab was chosen in 23 patients and TNF inhibitors were chosen in 88 patients as first line biologic agent. Complete/partial remission rates between TCZ and TNF inhibitors were similar at 3rd month and at the end of the follow-up. GC dose decrease (<4 mg) or discontinuation of GCs was achieved in a similar rate in both groups (TNF inhibitors vs TCZ: 78% vs 59%, p = 0.125). Drug survival rate was 56% in TNF inhibitors and 57% in TCZ group (p = 0.22). The use of concomitant conventional ISs did not affect the drug survival (HR =0.78, 95% CI =0.42-1.43, p = 0.42). The match analysis showed similar results between groups in terms of relapse, decrease in GC dose, surgery need and mortality. Conclusion: The efficacy and safety outcomes and drug survival rates seem to be similar for TNF inhibitors and tocilizumab in patients with Takayasu arteritis. (c) 2021 Elsevier Inc. All rights reserved.en_US
dc.identifier.doi10.1016/j.semarthrit.2021.09.010
dc.identifier.endpage1229en_US
dc.identifier.issn0049-0172
dc.identifier.issn1532-866X
dc.identifier.issue6en_US
dc.identifier.pmid34706312en_US
dc.identifier.scopus2-s2.0-85117723442en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage1224en_US
dc.identifier.urihttps://doi.org/10.1016/j.semarthrit.2021.09.010
dc.identifier.urihttps://hdl.handle.net/20.500.14551/24145
dc.identifier.volume51en_US
dc.identifier.wosWOS:000715072700004en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherW B Saunders Co-Elsevier Incen_US
dc.relation.ispartofSeminars In Arthritis And Rheumatismen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectTakayasu Arteritisen_US
dc.subjectBiologic Treatmenten_US
dc.subjectTocilizumaben_US
dc.subjectTNF Inhibitoren_US
dc.subjectDrug Survivalen_US
dc.subjectFactor Therapyen_US
dc.subjectDouble-Blinden_US
dc.subjectEfficacyen_US
dc.subjectManagementen_US
dc.subjectTrialen_US
dc.titleBiologic treatments in Takayasu's Arteritis: A comparative study of tumor necrosis factor inhibitors and tocilizumaben_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu